Jun 20,2024 TOP STORY

Economic Savings Model for Omada’s Cardiometabolic Programs

The study funded by Omada Health and conducted by Madison Noble, MPH, and Fang Chen, PhD, aimed to model the economic and health benefits of participating in virtual-first care (V1C) programs for cardiometabolic conditions. Using a microsimulation approach, the study focused on four types of programs: prevention, hypertension, diabetes, and diabetes plus hypertension. Participants showed sustained improvements in weight loss, hemoglobin A1c (HbA1c), and blood pressure (BP) levels, which were estimated to reduce disease onset by 2% to 10% over five years following enrollment. The study projected significant gross savings in healthcare expenditures. After one year, estimated savings ranged from $892 to $1342 per participant, with cumulative savings of $2963 to $4346 after three years, and $5221 to $7756 after five years.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jun 06,2024 TOP STORY

CureApp and Teijin Pharma Sign Agreement for Joint Marketing and Sales of Prescription Digital Therapeutic App for Hypertension

Teijin Pharma and CureApp have signed a joint agreement to market and sell CureApp HT, a prescription digital therapeutic app for hypertension, starting April 1st. CureApp HT, approved in Japan, supports lifestyle modifications essential for hypertension treatment. The partnership aims to expand CureApp HT’s use by leveraging Teijin Pharma's expertise in lifestyle-related medical devices and CureApp's digital therapeutics knowledge. This collaboration intends to improve patient adherence to lifestyle changes and overall management of hypertension, contributing to better patient outcomes and quality of life.

COLLABORATION PARTNERSHIP

#institution

#pdt

View Analyst & Ambassador Comments
Go to original news
May 09,2024

Welldoc Named “Best Overall Digital Health Company” for Second Consecutive Year in the 8th Annual MedTech Breakthrough Awards Program

Welldoc has won the "Best Overall Digital Health Company" award for the second consecutive year in the 8th annual MedTech Breakthrough Awards. The company's AI-powered platform offers flexible, multi-condition digital coaching across various health issues like diabetes, weight management, hypertension, heart failure, and prediabetes. It also provides personalized insights to empower individuals to manage their health better and offers critical data for clinical decision-making.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news
Apr 23,2024

Roche and VinCense to augment access to diabetes care in Tamil Nadu

Roche has forged a Memorandum of Understanding (MoU) with VinCense, a digital health monitoring service by MedIoTek Health Systems, to implement three programs in Madurai district, Tamil Nadu. These programs include screening 100,000 individuals over two years for diabetes, hypertension, and obesity, managing uncontrolled diabetes mellitus, and addressing tuberculosis-diabetes mellitus co-morbidity. The partnership aims to utilize integrated digital health solutions for early detection, intervention, and continuous care. Following a successful pilot phase from December 2022 to September 2023, where 67,370 individuals were screened, the initiative seeks to set new standards for accessible and technology-driven healthcare. The collaboration integrates Roche's expertise in public healthcare programs with VinCense's technology, enabling comprehensive health data recording and personalized dashboards for improved health insights.

COLLABORATION PARTNERSHIP

#connected device

#virtual care

View Analyst & Ambassador Comments
Go to original news
Apr 18,2024

Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution

DarioHealth announced two new contracts to provide integrated chronic condition management solutions for two employers beginning in the Q2 2024. The employers, a national supply chain company and a regional education organization, selected Dario's cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including support for individuals taking a GLP-1 medication.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news
Apr 18,2024

Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution

DarioHealth announced two new contracts to provide integrated chronic condition management solutions for two employers beginning in the Q2 2024. The employers, a national supply chain company and a regional education organization, selected Dario's cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including support for individuals taking a GLP-1 medication.

PRODUCT

#dtx

#coaching

View Analyst & Ambassador Comments
Go to original news
Mar 25,2024

Hello Heart Presents a New Report Showing Benefits for Seniors

A majority of study participants, all older adults, were able to reduce both their weight and blood pressure over periods of three and six months, the study showed. The latter result is significant because high blood pressure puts seniors at risk for almost all forms of heart disease and emergencies, including heart failure, stroke and related death. Surprisingly, the older adults who were part of the study had a 45% higher engagement rate with the app than younger members of Hello Heart, the results showed. Hello Heart also will be presenting an in-depth analysis of its study results at the upcoming American College of Cardiology 2024 Conference in Atlanta between April 6-8, the company announced.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 12,2024

Welldoc Announces CE Mark Certification

Welldoc announced that its flagship BlueStar mobile app has received CE mark certification as a Class IIa medical device under the European Union Medical Device Regulation (EU-MDR). This enables the company and their strategic partners to advance digital health solutions in the EU, addressing chronic condition needs that are rising globally. The announcement builds upon Welldoc’s existing 11 FDA clearances for type 1 and type 2 diabetes management capabilities, including advanced insulin dosing calculators. This milestone underscores the company’s continued commitment to the highest standards of quality, while also demonstrating extensive leadership in AI-based digital health solutions. 

REGULATORY CE MARK

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Feb 13,2024

Omada Health Enhances GLP-1 Care Track to Support Customers Managing Medications and Integrates MSK Support

Omada Health announced an expansion of its GLP-1 companion solution, adding customized partner support for medication eligibility and expanded exercise programming that leverages its musculoskeletal expertise. The enhanced GLP-1 Care Track, designed for the duration of GLP-1 medication use and afterward, will support Omada’s full cardiometabolic suite, which includes prevention, diabetes and hypertension programs. It leverages behavioral support, weight monitoring, nutrition, medication management education, and tailored exercise and movement plans designed by Omada’s physical therapists to optimize muscle mass, and builds on updates to the Omada for Prevention program announced in May 2023. Omada will track the impact during and after medication to demonstrate how the programming helps members maximize weight loss and keep it off.

PRODUCT

#virtual care

#coaching

View Analyst & Ambassador Comments
Go to original news
Feb 13,2024

Omada Health Enhances GLP-1 Care Track to Support Customers Managing Medications and Integrates MSK Support

Omada Health announced an expansion of its GLP-1 companion solution, adding customized partner support for medication eligibility and expanded exercise programming that leverages its musculoskeletal expertise. The enhanced GLP-1 Care Track, designed for the duration of GLP-1 medication use and afterward, will support Omada’s full cardiometabolic suite, which includes prevention, diabetes and hypertension programs. It leverages behavioral support, weight monitoring, nutrition, medication management education, and tailored exercise and movement plans designed by Omada’s physical therapists to optimize muscle mass, and builds on updates to the Omada for Prevention program announced in May 2023. Omada will track the impact during and after medication to demonstrate how the programming helps members maximize weight loss and keep it off.

PRODUCT

#dtx

#coaching

View Analyst & Ambassador Comments
Go to original news
Subscribe to HYPERTENSION